Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers
NCT ID: NCT04194918
Last Updated: 2020-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
25 participants
INTERVENTIONAL
2020-05-18
2020-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tobacco Cessation for Sexual Minorities
NCT03643679
Tailored Smoking Cessation Intervention in Promoting Sexual and Gender Minority Smokers to Quit Smoking
NCT03669120
Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens
NCT06308081
Avatar-led Acceptance and Commitment Therapy Smoking Cessation
NCT03631212
Avatar-Led Digital Therapeutic for Aiding Smoking Cessation in Sexual and Gender Minority Young Adults
NCT05847673
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Individuals will be recruited to use the Flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. Participants will also receive text messages providing motivational messages and review information discussed in the program. At the end of the intervention, participants will receive an email with all of the session handouts.
Participants are followed up with at 2 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prevention (Flexiquit+, text message, handout)
Individuals will be recruited to use the Flexiquit+ program consisting of 6 sessions, each lasting approximately 25 minutes. Participants will also receive text messages providing motivational messages and review information discussed in the program. At the end of the intervention, participants will receive an email with all of the session handouts.
Computer-Assisted Smoking Cessation Intervention
Use the Flexiquit+ program
Text Message
Receive text messages
Handout
Receive handouts via email
Questionnaire Administration
Ancillary studies
Quality-of-Life Assessment
Ancillary studies
Survey Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computer-Assisted Smoking Cessation Intervention
Use the Flexiquit+ program
Text Message
Receive text messages
Handout
Receive handouts via email
Questionnaire Administration
Ancillary studies
Quality-of-Life Assessment
Ancillary studies
Survey Administration
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must currently reside in the United States and anticipate remaining in the United States for the duration of the study (2 months)
* Participants must self-report smoking at least 1 cigarette per day in the 30 days prior to screening
* Participants must self-report having at least weekly internet access for the next two months
* Participants must self-report being willing and able to stream video online for this study
* Participants must self-report current use of a personal email account
* Participants must self-report current use of text messaging
* Participants must self-report that they are interested in participating in the study for themselves (versus \[vs\] someone else)
* Participants must self-report that they are not currently taking part in any other smoking cessation treatment such as the nicotine patch, nicotine gum, Zyban, in-person counseling, telephone counseling, using a web-based or app-based cessation program
* Participants must self-report that they have not participated in one of our prior smoking cessation studies, including the user-centered research conducted in the development of Flexiquit+
* Participants must self-report that they are comfortable reading, writing, and speaking English
* Participants must self-report that they understand and agree to the conditions of compensation
* Participants must self-report that they are not currently incarcerated in a prison
* Participants must be willing to use the Flexiquit+ program, complete the study assessments, and sign an online consent form
18 Years
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
The Safeway Foundation
UNKNOWN
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaimee Heffner
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-08031
Identifier Type: REGISTRY
Identifier Source: secondary_id
10396
Identifier Type: OTHER
Identifier Source: secondary_id
RG1004771
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.